Annual report
3353.TEDINET S100Y4Y9
Period2025-03-01 → 2026-02-28
Filed2026-05-19
StandardJapan GAAP
ConsolidatedYes
Data checks22 of 22 passed
Key figures · 145
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥55.0bn | 2025-03-01 → 2026-02-28 | Cons. | Net sales |
| Revenue | ¥48.4bn | 2024-03-01 → 2025-02-28 | Cons. | Net sales |
| Revenue | ¥39.9bn | 2023-03-01 → 2024-02-29v | Cons. | Net sales (5-year summary) |
| Revenue | ¥33.9bn | 2022-03-01 → 2023-02-28v | Cons. | Net sales (5-year summary) |
| Revenue | ¥33.6bn | 2021-03-01 → 2022-02-28d | Cons. | Net sales (5-year summary) |
| Operating income | ¥1.8bn | 2025-03-01 → 2026-02-28 | Cons. | Operating income |
| Operating income | ¥1.7bn | 2024-03-01 → 2025-02-28 | Cons. | Operating income |
| Ordinary income | ¥1.9bn | 2025-03-01 → 2026-02-28 | Cons. | Ordinary income |
| Ordinary income | ¥1.8bn | 2024-03-01 → 2025-02-28 | Cons. | Ordinary income |
| Ordinary income | ¥1.8bn | 2023-03-01 → 2024-02-29v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.2bn | 2022-03-01 → 2023-02-28v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.4bn | 2021-03-01 → 2022-02-28d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.0bn | 2025-03-01 → 2026-02-28 | Cons. | Income before income taxes |
| Profit before tax | ¥1.9bn | 2024-03-01 → 2025-02-28 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.3bn | 2025-03-01 → 2026-02-28 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.1bn | 2024-03-01 → 2025-02-28 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.0bn | 2023-03-01 → 2024-02-29v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥760m | 2022-03-01 → 2023-02-28v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥852m | 2021-03-01 → 2022-02-28d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥1.3bn | 2025-03-01 → 2026-02-28 | Cons. | Profit loss |
| Net income | ¥1.1bn | 2024-03-01 → 2025-02-28 | Cons. | Profit loss |
| Total assets | ¥37.6bn | at 2026-02-28 | Cons. | Assets |
| Total assets | ¥34.2bn | at 2025-02-28 | Cons. | Assets |
| Total assets | ¥31.7bn | at 2024-02-29v | Cons. | Total assets (5-year summary) |
| Total assets | ¥27.5bn | at 2023-02-28v | Cons. | Total assets (5-year summary) |
| Total assets | ¥29.1bn | at 2022-02-28d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥21.2bn | at 2026-02-28 | Cons. | Liabilities |
| Total liabilities | ¥19.5bn | at 2025-02-28 | Cons. | Liabilities |
| Net assets / equity | ¥16.3bn | at 2026-02-28 | Cons. | Net assets |
| Net assets / equity | ¥14.7bn | at 2025-02-28 | Cons. | Net assets |
| Net assets / equity | ¥13.8bn | at 2024-02-29v | Cons. | Net assets |
| Net assets / equity | ¥12.6bn | at 2023-02-28v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥11.9bn | at 2022-02-28d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥6.1bn | at 2026-02-28 | Cons. | Cash and deposits |
| Cash and deposits | ¥6.8bn | at 2025-02-28 | Cons. | Cash and deposits |
| Cash & equivalents | ¥5.7bn | at 2026-02-28 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.6bn | at 2025-02-28 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.6bn | at 2024-02-29v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.3bn | at 2023-02-28v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥7.8bn | at 2022-02-28d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥1.2bn | 2025-03-01 → 2026-02-28 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.2bn | 2024-03-01 → 2025-02-28 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥4.3bn | 2023-03-01 → 2024-02-29v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.3bn | 2022-03-01 → 2023-02-28v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.1bn | 2021-03-01 → 2022-02-28d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥1.8bn | 2025-03-01 → 2026-02-28 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2024-03-01 → 2025-02-28 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.2bn | 2023-03-01 → 2024-02-29v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥478m | 2022-03-01 → 2023-02-28v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥216m | 2021-03-01 → 2022-02-28d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥284m | 2025-03-01 → 2026-02-28 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.0bn | 2024-03-01 → 2025-02-28 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥278m | 2023-03-01 → 2024-02-29v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.4bn | 2022-03-01 → 2023-02-28v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥65m | 2021-03-01 → 2022-02-28d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥338.73 | 2025-03-01 → 2026-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥301.35 | 2024-03-01 → 2025-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥276.7 | 2023-03-01 → 2024-02-29v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥202.2 | 2022-03-01 → 2023-02-28v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥226.92 | 2021-03-01 → 2022-02-28d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥4,164.98 | at 2026-02-28 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,747.7 | at 2025-02-28 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,523.25 | at 2024-02-29v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,207.14 | at 2023-02-28v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,030.61 | at 2022-02-28d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 41.7% | at 2026-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.2% | at 2025-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.8% | at 2024-02-29v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.8% | at 2023-02-28v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.1% | at 2022-02-28d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 8.6% | 2025-03-01 → 2026-02-28 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.3% | 2024-03-01 → 2025-02-28 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2023-03-01 → 2024-02-29v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.5% | 2022-03-01 → 2023-02-28v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.8% | 2021-03-01 → 2022-02-28d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,608 | at 2026-02-28 | Cons. | Number of employees |
| Employees | 1,547 | at 2025-02-28 | Cons. | Number of employees |
| Employees | 1,431 | at 2024-02-29v | Cons. | Number of employees |
| Employees | 1,297 | at 2023-02-28v | Cons. | Number of employees |
| Employees | 1,325 | at 2022-02-28d | Cons. | Number of employees |
| Revenue | ¥908m | 2025-03-01 → 2026-02-28 | Standalone | Operating revenue1 |
| Revenue | ¥1.3bn | 2024-03-01 → 2025-02-28 | Standalone | Operating revenue1 |
| Operating income | ¥183m | 2025-03-01 → 2026-02-28 | Standalone | Operating income |
| Operating income | ¥620m | 2024-03-01 → 2025-02-28 | Standalone | Operating income |
| Ordinary income | ¥254m | 2025-03-01 → 2026-02-28 | Standalone | Ordinary income |
| Ordinary income | ¥680m | 2024-03-01 → 2025-02-28 | Standalone | Ordinary income |
| Ordinary income | ¥616m | 2023-03-01 → 2024-02-29v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥592m | 2022-03-01 → 2023-02-28v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥432m | 2021-03-01 → 2022-02-28d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥247m | 2025-03-01 → 2026-02-28 | Standalone | Income before income taxes |
| Profit before tax | ¥752m | 2024-03-01 → 2025-02-28 | Standalone | Income before income taxes |
| Net income | ¥166m | 2025-03-01 → 2026-02-28 | Standalone | Profit loss |
| Net income | ¥616m | 2024-03-01 → 2025-02-28 | Standalone | Profit loss |
| Net income | ¥457m | 2023-03-01 → 2024-02-29v | Standalone | Net income loss (5-year summary) |
| Net income | ¥526m | 2022-03-01 → 2023-02-28v | Standalone | Net income loss (5-year summary) |
| Net income | ¥397m | 2021-03-01 → 2022-02-28d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥12.6bn | at 2026-02-28 | Standalone | Assets |
| Total assets | ¥13.1bn | at 2025-02-28 | Standalone | Assets |
| Total assets | ¥12.7bn | at 2024-02-29v | Standalone | Total assets (5-year summary) |
| Total assets | ¥11.8bn | at 2023-02-28v | Standalone | Total assets (5-year summary) |
| Total assets | ¥12.5bn | at 2022-02-28d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥3.4bn | at 2026-02-28 | Standalone | Liabilities |
| Total liabilities | ¥3.7bn | at 2025-02-28 | Standalone | Liabilities |
| Net assets / equity | ¥9.2bn | at 2026-02-28 | Standalone | Net assets |
| Net assets / equity | ¥9.4bn | at 2025-02-28 | Standalone | Net assets |
| Net assets / equity | ¥9.0bn | at 2024-02-29v | Standalone | Net assets |
| Net assets / equity | ¥8.6bn | at 2023-02-28v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥8.3bn | at 2022-02-28d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥356m | at 2026-02-28 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.2bn | at 2025-02-28 | Standalone | Cash and deposits |
| EPS (basic) | ¥43.98 | 2025-03-01 → 2026-02-28 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥163.72 | 2024-03-01 → 2025-02-28 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥121.61 | 2023-03-01 → 2024-02-29v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥140.07 | 2022-03-01 → 2023-02-28v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥105.69 | 2021-03-01 → 2022-02-28d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥120 | 2025-03-01 → 2026-02-28 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥65 | 2024-03-01 → 2025-02-28 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥45 | 2023-03-01 → 2024-02-29v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2022-03-01 → 2023-02-28v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2021-03-01 → 2022-02-28d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,450.13 | at 2026-02-28 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,498.76 | at 2025-02-28 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,385.18 | at 2024-02-29v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,293.7 | at 2023-02-28v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,196.84 | at 2022-02-28d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 73.1% | at 2026-02-28 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 72.0% | at 2025-02-28 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.8% | at 2024-02-29v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.2% | at 2023-02-28v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.3% | at 2022-02-28d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 1.8% | 2025-03-01 → 2026-02-28 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.7% | 2024-03-01 → 2025-02-28 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.2% | 2023-03-01 → 2024-02-29v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.2% | 2022-03-01 → 2023-02-28v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.9% | 2021-03-01 → 2022-02-28d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 3,770,000 | at 2026-02-28 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,070,000 | at 2025-02-28 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,070,000 | at 2024-02-29v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,070,000 | at 2023-02-28v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,070,000 | at 2022-02-28d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 30 | at 2026-02-28 | Standalone | Number of employees |
| Employees | 30 | at 2025-02-28 | Standalone | Number of employees |
| Employees | 22 | at 2024-02-29v | Standalone | Number of employees |
| Employees | 25 | at 2023-02-28v | Standalone | Number of employees |
| Employees | 25 | at 2022-02-28d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 86
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2025-03-01 → 2026-02-28 | ¥175m |
| Reconciling Itemsreconciling | depreciation | 2025-03-01 → 2026-02-28 | ¥44m |
| Reconciling Itemsreconciling | revenue | 2025-03-01 → 2026-02-28 | −¥1.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-03-01 → 2026-02-28 | −¥1.2bn |
| Reconciling Itemsreconciling | segment assets | at 2026-02-28 | ¥10.0bn |
| Reconciling Itemsreconciling | segment profit | 2025-03-01 → 2026-02-28 | −¥129m |
| Dispensing Pharmacyreportable segment | capex | 2025-03-01 → 2026-02-28 | ¥212m |
| Dispensing Pharmacyreportable segment | depreciation | 2025-03-01 → 2026-02-28 | ¥184m |
| Dispensing Pharmacyreportable segment | employees | at 2026-02-28 | 500 pure |
| Dispensing Pharmacyreportable segment | revenue | 2025-03-01 → 2026-02-28 | ¥26.3bn |
| Dispensing Pharmacyreportable segment | revenue external | 2025-03-01 → 2026-02-28 | ¥26.3bn |
| Dispensing Pharmacyreportable segment | segment assets | at 2026-02-28 | ¥7.4bn |
| Dispensing Pharmacyreportable segment | segment profit | 2025-03-01 → 2026-02-28 | ¥1.4bn |
| Health Carereportable segment | capex | 2025-03-01 → 2026-02-28 | ¥117m |
| Health Carereportable segment | depreciation | 2025-03-01 → 2026-02-28 | ¥410m |
| Health Carereportable segment | employees | at 2026-02-28 | 833 pure |
| Health Carereportable segment | revenue | 2025-03-01 → 2026-02-28 | ¥9.0bn |
| Health Carereportable segment | revenue external | 2025-03-01 → 2026-02-28 | ¥9.0bn |
| Health Carereportable segment | revenue intersegment | 2025-03-01 → 2026-02-28 | ¥800,000 |
| Health Carereportable segment | segment assets | at 2026-02-28 | ¥10.7bn |
| Health Carereportable segment | segment profit | 2025-03-01 → 2026-02-28 | ¥112m |
| Medical Products Wholesalereportable segment | capex | 2025-03-01 → 2026-02-28 | ¥38m |
| Medical Products Wholesalereportable segment | depreciation | 2025-03-01 → 2026-02-28 | ¥25m |
| Medical Products Wholesalereportable segment | employees | at 2026-02-28 | 243 pure |
| Medical Products Wholesalereportable segment | revenue | 2025-03-01 → 2026-02-28 | ¥20.6bn |
| Medical Products Wholesalereportable segment | revenue external | 2025-03-01 → 2026-02-28 | ¥19.4bn |
| Medical Products Wholesalereportable segment | revenue intersegment | 2025-03-01 → 2026-02-28 | ¥1.2bn |
| Medical Products Wholesalereportable segment | segment assets | at 2026-02-28 | ¥6.7bn |
| Medical Products Wholesalereportable segment | segment profit | 2025-03-01 → 2026-02-28 | ¥287m |
| Real Estatereportable segment | capex | 2025-03-01 → 2026-02-28 | ¥3m |
| Real Estatereportable segment | depreciation | 2025-03-01 → 2026-02-28 | ¥59m |
| Real Estatereportable segment | employees | at 2026-02-28 | 1 pure |
| Real Estatereportable segment | revenue | 2025-03-01 → 2026-02-28 | ¥265m |
| Real Estatereportable segment | revenue external | 2025-03-01 → 2026-02-28 | ¥254m |
| Real Estatereportable segment | revenue intersegment | 2025-03-01 → 2026-02-28 | ¥11m |
| Real Estatereportable segment | segment assets | at 2026-02-28 | ¥2.8bn |
| Real Estatereportable segment | segment profit | 2025-03-01 → 2026-02-28 | ¥145m |
| Total Of Reportable Segments And Otherssegment total | capex | 2025-03-01 → 2026-02-28 | ¥369m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-03-01 → 2026-02-28 | ¥678m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-03-01 → 2026-02-28 | ¥56.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-03-01 → 2026-02-28 | ¥55.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-03-01 → 2026-02-28 | ¥1.2bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2026-02-28 | ¥27.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-03-01 → 2026-02-28 | ¥1.9bn |
| Reconciling Itemsreconciling | capex | 2024-03-01 → 2025-02-28 | ¥61m |
| Reconciling Itemsreconciling | depreciation | 2024-03-01 → 2025-02-28 | ¥36m |
| Reconciling Itemsreconciling | revenue | 2024-03-01 → 2025-02-28 | −¥846m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-03-01 → 2025-02-28 | −¥846m |
| Reconciling Itemsreconciling | segment assets | at 2025-02-28 | ¥9.2bn |
| Reconciling Itemsreconciling | segment profit | 2024-03-01 → 2025-02-28 | −¥188m |
| Dispensing Pharmacyreportable segment | capex | 2024-03-01 → 2025-02-28 | ¥200m |
| Dispensing Pharmacyreportable segment | depreciation | 2024-03-01 → 2025-02-28 | ¥187m |
| Dispensing Pharmacyreportable segment | revenue | 2024-03-01 → 2025-02-28 | ¥24.7bn |
| Dispensing Pharmacyreportable segment | revenue external | 2024-03-01 → 2025-02-28 | ¥24.7bn |
| Dispensing Pharmacyreportable segment | segment assets | at 2025-02-28 | ¥7.5bn |
| Dispensing Pharmacyreportable segment | segment profit | 2024-03-01 → 2025-02-28 | ¥1.2bn |
| Health Carereportable segment | capex | 2024-03-01 → 2025-02-28 | ¥790m |
| Health Carereportable segment | depreciation | 2024-03-01 → 2025-02-28 | ¥349m |
| Health Carereportable segment | revenue | 2024-03-01 → 2025-02-28 | ¥8.1bn |
| Health Carereportable segment | revenue external | 2024-03-01 → 2025-02-28 | ¥8.1bn |
| Health Carereportable segment | revenue intersegment | 2024-03-01 → 2025-02-28 | ¥600,000 |
| Health Carereportable segment | segment assets | at 2025-02-28 | ¥9.4bn |
| Health Carereportable segment | segment profit | 2024-03-01 → 2025-02-28 | ¥163m |
| Medical Products Wholesalereportable segment | capex | 2024-03-01 → 2025-02-28 | ¥23m |
| Medical Products Wholesalereportable segment | depreciation | 2024-03-01 → 2025-02-28 | ¥11m |
| Medical Products Wholesalereportable segment | revenue | 2024-03-01 → 2025-02-28 | ¥16.2bn |
| Medical Products Wholesalereportable segment | revenue external | 2024-03-01 → 2025-02-28 | ¥15.4bn |
| Medical Products Wholesalereportable segment | revenue intersegment | 2024-03-01 → 2025-02-28 | ¥841m |
| Medical Products Wholesalereportable segment | segment assets | at 2025-02-28 | ¥6.1bn |
| Medical Products Wholesalereportable segment | segment profit | 2024-03-01 → 2025-02-28 | ¥345m |
| Real Estatereportable segment | depreciation | 2024-03-01 → 2025-02-28 | ¥42m |
| Real Estatereportable segment | revenue | 2024-03-01 → 2025-02-28 | ¥208m |
| Real Estatereportable segment | revenue external | 2024-03-01 → 2025-02-28 | ¥204m |
| Real Estatereportable segment | revenue intersegment | 2024-03-01 → 2025-02-28 | ¥5m |
| Real Estatereportable segment | segment assets | at 2025-02-28 | ¥2.1bn |
| Real Estatereportable segment | segment profit | 2024-03-01 → 2025-02-28 | ¥138m |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-03-01 → 2025-02-28 | ¥1.0bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-03-01 → 2025-02-28 | ¥589m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-03-01 → 2025-02-28 | ¥49.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-03-01 → 2025-02-28 | ¥48.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-03-01 → 2025-02-28 | ¥846m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-02-28 | ¥25.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-03-01 → 2025-02-28 | ¥1.9bn |
| Dispensing Pharmacyreportable segment | employees | at 2026-02-28 | 2 pure |
| Health Carereportable segment | employees | at 2026-02-28 | 1 pure |
| Real Estatereportable segment | employees | at 2026-02-28 | 1 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,671
| Item | Context | Value | Unit |
|---|---|---|---|
| Term of office information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E03443-000HisakiKunihikoMember | Original text (Japanese)(注)５ | |
| Footnotes directors and corporate auditors proposal (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Footnotes directors and corporate auditors proposal (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Footnotes directors and corporate auditors proposal (text) | FilingDateInstant_Row3Member | Text · Plus | |
| Footnotes directors and corporate auditors proposal (text) | FilingDateInstant_Row4Member | Text · Plus | |
| Footnotes directors and corporate auditors proposal (text) | FilingDateInstant_Row5Member | Text · Plus | |
| Outside directors and outside corporate auditors (text) | FilingDateInstant | Text · Plus | |
| Audits (text) | FilingDateInstant | Text · Plus | |
| Remuneration for directors and other officers (text) | FilingDateInstant | Text · Plus | |
| Remuneration etc paid by group to each director or other officer (text) | FilingDateInstant | Text · Plus | |
| Shareholdings (text) | FilingDateInstant | Text · Plus | |
| Name of group company holding largest amount of investment shares in group | CurrentYearInstant | Original text (Japanese)㈱ヘルスケア・キャピタル | |
| Reason for increase in number of shares shares not listed investment shares held for purposes other than pure investment largest holding company | CurrentYearDuration | － | |
| Reason for increase in number of shares shares other than those not listed investment shares held for purposes other than pure investment largest holding company | CurrentYearDuration | － | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)㈱百五銀行 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)円滑な金融取引関係の維持および強化のため保有しておりましたが、保有効果を検証した結果、純投資目的へ変更いたしました。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)無 | |
| Footnotes specified investment shares held for purposes other than pure investment largest holding company (text) | CurrentYearInstant_Row1Member | Text · Plus | |
| Name of securities investment equity securities reclassified from held for purposes other than pure investment to held for pure investment largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)㈱百五銀行 | |
| Fiscal year of change in purpose of shareholding investment shares reclassified from held for purposes other than pure investment to held for pure investment largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)2026年２月期 | |
| Reason for change in purpose of shareholding and policy on holding or sale of shares after change investment shares reclassified from held for purposes other than pure investment to held for pure investment largest holding company | CurrentYearInstant_Row1Member | Text · Plus | |
| Reason for increase in number of shares shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | － | |
| Reason for increase in number of shares shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | Original text (Japanese)取引先との関係強化のため、取引先持株会を通じて株式の取得をしております。 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)サワイグループホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)有 | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row1Member | Text · Plus | |
| Name of securities investment equity securities reclassified from held for purposes other than pure investment to held for pure investment reporting company | Prior2YearInstant_Row1Member | Original text (Japanese)クオールホールディングス㈱ | |
| Fiscal year of change in purpose of shareholding investment shares reclassified from held for purposes other than pure investment to held for pure investment reporting company | Prior2YearInstant_Row1Member | Original text (Japanese)2024年２月期 | |
| Reason for change in purpose of shareholding and policy on holding or sale of shares after change investment shares reclassified from held for purposes other than pure investment to held for pure investment reporting company | Prior2YearInstant_Row1Member | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Description of fact that financial statements have been prepared in accordance with special provision financial information | CurrentYearDuration | Original text (Japanese)また、当社は特例財務諸表提出会社に該当し、財務諸表等規則第127条の規定により財務諸表を作成しております。 | |
| Note on independent audit financial information | CurrentYearDuration | Text · Plus | |
| Remarkable efforts to ensure fair presentation of consolidated financial statements etc financial information | CurrentYearDuration | Text · Plus | |
| Consolidated balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of changes in equity (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of cash flows (text) | CurrentYearDuration | Text · Plus | |
| Notes significant accounting policies for preparation of consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Number of consolidated subsidiaries and names of major consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Changes in scope of consolidation (text) | CurrentYearDuration | Text · Plus | |
| Number of unconsolidated subsidiaries and associates accounted for using equity method and names of major entities accounted for using equity method (text) | CurrentYearDuration | Text · Plus | |
| Disclosure about fiscal years etc of consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Disclosure of accounting policies (text) | CurrentYearDuration | Text · Plus | |
| Significant accounting estimates consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes new accounting standards not yet applied consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes changes in presentation consolidated financial statements (text) | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 22 of 22 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |